Jonathan Alexander Terán Trujillo
Research Interests
Jonathan Alexander Terán Trujillo has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Israel Arellano González
Investigador independiente, Ciudad de México, México
1 shared publication - Leonardo Lanzee Mendoza Jiménez
Investigador Independiente
1 shared publication - Telmo Eduardo Salas Joya
Hospital IESS Manta, Ecuador
1 shared publication
Latest Publications
- Open Access
- 16 September 2026
- Published by InvestiGO in VitalyScience Revista Científica Multidisciplinaria
- Vol. 4 (11) , 57-70
INTELIGENCIA ARTIFICIAL PARA EL CRIBADO DE RETINOPATÍA DIABÉTICA: PRECISIÓN DIAGNÓSTICA, IMPLEMENTACIÓN EN ENTORNOS REALES Y DESAFÍOS ÉTICOS
Diabetic retinopathy (DR) is the leading cause of preventable blindness among working-age adults, and its prevalence is increasing in line with the global spread of diabetes mellitus. Objective: To analyze the scientific evidence published from 2016 to 2026 regarding the diagnostic accuracy of artificial intelligence (AI) for DR screening, its application in real-world clinical practice, and the ethics of its use. A systematic narrative literature review was conducted according to the PRISMA 2020 guidelines, involving a search of indexed databases (PubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Library) for primary studies, systematic reviews, and meta-analyses published in high-impact journals. Deep learning algorithms achieve sensitivities and specificities exceeding 90% in the detection of referable PR under rigorous laboratory conditions; however, these algorithms face limitations in their diagnostic performance in external populations, particularly in low- and middle-income countries. Studies on the implementation of AI within national screening programs document increases in coverage and reductions in costs, although gaps in generalizability still persist due to issues with the representativeness of training datasets. From an ethical perspective, we identify risks of algorithmic bias, equity gaps, issues of clinical accountability, and informed consent. AI is viewed as a tool with the potential to increase access to RD screening, although its use requires rigorous external studies to validate its performance, the creation of clear regulatory frameworks, and the implementation of strategies to mitigate bias.
- 16 September 2026
- Published by InvestiGO in VitalyScience Revista Científica Multidisciplinaria
- Vol. 4 (11) , 57-70
Open AccessINTELIGENCIA ARTIFICIAL PARA EL CRIBADO DE RETINOPATÍA DIABÉTICA: PRECISIÓN DIAGNÓSTICA, IMPLEMENTACIÓN EN ENTORNOS REALES Y DESAFÍOS ÉTICOS
Diabetic retinopathy (DR) is the leading cause of preventable blindness among working-age adults, and its prevalence is increasing in line with the global spread of diabetes mellitus. Objective: To analyze the scientific evidence published from 2016 to 2026 regarding the diagnostic accuracy of artificial intelligence (AI) for DR screening, its application in real-world clinical practice, and the ethics of its use. A systematic narrative literature review was conducted according to the PRISMA 2020 guidelines, involving a search of indexed databases (PubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Library) for primary studies, systematic reviews, and meta-analyses published in high-impact journals. Deep learning algorithms achieve sensitivities and specificities exceeding 90% in the detection of referable PR under rigorous laboratory conditions; however, these algorithms face limitations in their diagnostic performance in external populations, particularly in low- and middle-income countries. Studies on the implementation of AI within national screening programs document increases in coverage and reductions in costs, although gaps in generalizability still persist due to issues with the representativeness of training datasets. From an ethical perspective, we identify risks of algorithmic bias, equity gaps, issues of clinical accountability, and informed consent. AI is viewed as a tool with the potential to increase access to RD screening, although its use requires rigorous external studies to validate its performance, the creation of clear regulatory frameworks, and the implementation of strategies to mitigate bias.